<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37094946</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000870</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000870</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Friend leukaemia virus integration 1 (Fli-1) regulates chemokine/cytokine expression and thus plays an important role in the development of lupus nephritis. Chemokine CXC ligand 13 (CXCL13) is a chemokine that promotes the formation of ectopic lymphoid structures and has been reported to be associated with the pathogenesis of lupus nephritis. The relationship between Fli-1 and CXCL13 is unknown. This study aims to elucidate whether Fli-1 impacts CXCL13 expression and contributes to the progression of lupus-like nephritis in adult MRL/lpr mouse.</AbstractText><AbstractText Label="METHODS">Serum CXCL13 levels were measured in adult wild-type (WT) MRL/lpr mice and Fli-1 heterozygote knockout (Fli-1<sup>+/-</sup>) MRL/lpr mice (4 months old or older) using ELISA. Renal mRNA expression (CXCL13 and related molecules) was measured using real-time PCR method. Kidneys were removed, stained and evaluated using a pathology scoring system. The grade of CXCL13 or CXC-chemokine receptor type 5 (CXCR5)-positive immune cell infiltration into the kidney was evaluated using immunostaining with anti-CXCL13 or anti-CXCR5 antibodies. We also used immunofluorescence staining with CXCL13- and CD11b-specific antibodies to detect the infiltration of CXCL13/CD11b double-positive immune cells.</AbstractText><AbstractText Label="RESULTS">Serum CXCL13 levels in Fli-1<sup>+/-</sup> MRL/lpr mice were significantly lower than that in WT MRL/lpr mice (545.5 and 960.5&#x2009;pg/mL, p=0.02). Renal expression of CXCL13 mRNA and SRY-related HMG box4 (Sox4) (an important factor for B-cell development) levels were significantly lower in Fli-1<sup>+/-</sup> MRL/lpr mice. Renal histology scores in WT MRL/lpr mice revealed significantly increased glomerular inflammation. Despite similar interstitial immune cell infiltration into the kidney, the number of CXCL13- and CXCR5-positive cells was significantly lower in Fli-1<sup>+/-</sup> MRL/lpr mice than in WT mice. Furthermore, immunofluorescence staining revealed that Fli-1<sup>+/-</sup>MRL/lpr mice had significantly fewer CXCL13/CD11b double-positive immune cells.</AbstractText><AbstractText Label="CONCLUSION">Fli-1 regulates renal Sox4 mRNA expression and infiltration of CXCR5-positive cells as well as CXCL13/CD11b double-positive immune cells into the kidney, which affects CXCL13 expression and lupus-like nephritis.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shuzo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8110-8261</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan shuzo@fmu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xian K</ForeName><Initials>XK</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumichika</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Haruki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temmoku</LastName><ForeName>Jumpei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asano</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migita</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C083431">SOX4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055751">SOXC Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055751" MajorTopicYN="N">SOXC Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemokines</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37094946</ArticleId><ArticleId IdType="pmc">PMC10152041</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000870</ArticleId><ArticleId IdType="pii">10/1/e000870</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 2020;21:605&#x2013;14. 10.1038/s41590-020-0677-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Zhang XK. The friend leukaemia virus integration 1 (fli-1) transcription factor affects lupus nephritis development by regulating inflammatory cell infiltration into the kidney. Clin Exp Immunol 2014;177:102&#x2013;9. 10.1111/cei.12310</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12310</ArticleId><ArticleId IdType="pmc">PMC4089159</ArticleId><ArticleId IdType="pubmed">24580413</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J 2018;11:207&#x2013;18. 10.1093/ckj/sfx093</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfx093</ArticleId><ArticleId IdType="pmc">PMC5888814</ArticleId><ArticleId IdType="pubmed">29644061</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011;13:250. 10.1186/ar3528</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3528</ArticleId><ArticleId IdType="pmc">PMC3334648</ArticleId><ArticleId IdType="pubmed">22192660</ArticleId></ArticleIdList></Reference><Reference><Citation>Adalid-Peralta L, Mathian A, Tran T, et al. . Leukocytes and the kidney contribute to interstitial inflammation in lupus nephritis. Kidney Int 2008;73:172&#x2013;80. 10.1038/sj.ki.5002625</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5002625</ArticleId><ArticleId IdType="pubmed">17928821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front Biosci 2008;13:3312&#x2013;20. 10.2741/2927</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2927</ArticleId><ArticleId IdType="pubmed">18508434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011;2011:432595. 10.1155/2011/432595</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/432595</ArticleId><ArticleId IdType="pmc">PMC3196871</ArticleId><ArticleId IdType="pubmed">22028588</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Pirapakaran T, Luo XM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators Inflamm 2016;2016:6012715. 10.1155/2016/6012715</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6012715</ArticleId><ArticleId IdType="pmc">PMC4923605</ArticleId><ArticleId IdType="pubmed">27403037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013;24:1357&#x2013;66. 10.1681/ASN.2013010026</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2013010026</ArticleId><ArticleId IdType="pmc">PMC3752952</ArticleId><ArticleId IdType="pubmed">23929771</ArticleId></ArticleIdList></Reference><Reference><Citation>Legler DF, Loetscher M, Roos RS, et al. . B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655&#x2013;60. 10.1084/jem.187.4.655</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.187.4.655</ArticleId><ArticleId IdType="pmc">PMC2212150</ArticleId><ArticleId IdType="pubmed">9463416</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn MD, Ngo VN, Ansel KM, et al. . A B-cell-homing chemokine made in lymphoid follicles activates burkitt&#x2019;s lymphoma receptor-1. Nature 1998;391:799&#x2013;803. 10.1038/35876</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35876</ArticleId><ArticleId IdType="pubmed">9486651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa S, Sato T, Abe M, et al. . Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by c11b+cd11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 2001;193:1393&#x2013;402. 10.1084/jem.193.12.1393</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.193.12.1393</ArticleId><ArticleId IdType="pmc">PMC2193305</ArticleId><ArticleId IdType="pubmed">11413194</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz O, Hammerschmidt SI, Moschovakis GL, et al. . Chemokines and chemokine receptors in lymphoid tissue dynamics. Annu Rev Immunol 2016;34:203&#x2013;42. 10.1146/annurev-immunol-041015-055649</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055649</ArticleId><ArticleId IdType="pubmed">26907216</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, Zhu T, Liu Y, et al. . Role of the CXCL13/CXCR5 axis in autoimmune diseases. Front Immunol 2022;13:850998. 10.3389/fimmu.2022.850998</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.850998</ArticleId><ArticleId IdType="pmc">PMC8931035</ArticleId><ArticleId IdType="pubmed">35309354</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621&#x2013;63. 10.1146/annurev-immunol-031210-101400</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101400</ArticleId><ArticleId IdType="pubmed">21314428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansel KM, Harris RBS, Cyster JG. Cxcl13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002;16:67&#x2013;76. 10.1016/s1074-7613(01)00257-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1074-7613(01)00257-6</ArticleId><ArticleId IdType="pubmed">11825566</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M, Adah D, Tariq M, et al. . CXCL13/CXCR5 signaling axis in cancer. Life Sciences 2019;227:175&#x2013;86. 10.1016/j.lfs.2019.04.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.04.053</ArticleId><ArticleId IdType="pubmed">31026453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H-T, Shiao Y-M, Wu T-H, et al. . Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 2010;37:45&#x2013;52. 10.3899/jrheum.090450</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090450</ArticleId><ArticleId IdType="pubmed">19955043</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Z, Li L, Zhu J, et al. . Cxcl13 promotes proliferation of mesangial cells by combination with CXCR5 in SLE. J Immunol Res 2016;2016:2063985. 10.1155/2016/2063985</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2063985</ArticleId><ArticleId IdType="pmc">PMC5031877</ArticleId><ArticleId IdType="pubmed">27672667</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiener A, Schippers A, Wagner N, et al. . Cxcr5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking. Clin Exp Immunol 2016;185:22&#x2013;32. 10.1111/cei.12791</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12791</ArticleId><ArticleId IdType="pmc">PMC4908294</ArticleId><ArticleId IdType="pubmed">26990531</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz OM, Velden J, Kneissler U, et al. . Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int 2008;74:448&#x2013;57. 10.1038/ki.2008.191</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2008.191</ArticleId><ArticleId IdType="pubmed">18528326</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer L, Worthmann K, Haller H, et al. . CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside? Clin Exp Immunol 2015;179:85&#x2013;9. 10.1111/cei.12439</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12439</ArticleId><ArticleId IdType="pmc">PMC4260900</ArticleId><ArticleId IdType="pubmed">25138065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu T, Trojanowska M, Watson DK. Ets proteins in biological control and cancer. J Cell Biochem 2004;91:896&#x2013;903. 10.1002/jcb.20012</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.20012</ArticleId><ArticleId IdType="pmc">PMC2265084</ArticleId><ArticleId IdType="pubmed">15034925</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos DD, Pharr PN, Lavenburg KR, et al. . Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the fli1 transcription factor. Mol Cell Biol 2000;20:5643&#x2013;52. 10.1128/MCB.20.15.5643-5652.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.20.15.5643-5652.2000</ArticleId><ArticleId IdType="pmc">PMC86032</ArticleId><ArticleId IdType="pubmed">10891501</ArticleId></ArticleIdList></Reference><Reference><Citation>Papas TS, Bhat NK, Spyropoulos DD, et al. . Functional relationships among ETS gene family members. Leukemia 1997;11 Suppl 3:557&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9209455</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 2006;54:385&#x2013;95. 10.1369/jhc.4A6514.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1369/jhc.4A6514.2005</ArticleId><ArticleId IdType="pubmed">16234507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XK, Gallant S, Molano I, et al. . Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol 2004;173:6481&#x2013;9. 10.4049/jimmunol.173.10.6481</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.10.6481</ArticleId><ArticleId IdType="pubmed">15528390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathenia J, Reyes-Cortes E, Williams S, et al. . Impact of Fli-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice. Clin Exp Immunol 2010;162:362&#x2013;71. 10.1111/j.1365-2249.2010.04245.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2010.04245.x</ArticleId><ArticleId IdType="pmc">PMC2996603</ArticleId><ArticleId IdType="pubmed">20731671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Eddy A, Teng YT, et al. . An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the Ets family of transcription factor genes. Mol Cell Biol 1995;15:6961&#x2013;70. 10.1128/MCB.15.12.6961</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.15.12.6961</ArticleId><ArticleId IdType="pmc">PMC230951</ArticleId><ArticleId IdType="pubmed">8524263</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki E, Karam E, Williams S, et al. . Fli-1 transcription factor affects glomerulonephritis development by regulating expression of monocyte chemoattractant protein-1 in endothelial cells in the kidney. Clin Immunol 2012;145:201&#x2013;8. 10.1016/j.clim.2012.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2012.09.006</ArticleId><ArticleId IdType="pmc">PMC3501541</ArticleId><ArticleId IdType="pubmed">23108091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Lennard Richard M, Brandon D, et al. . A critical role of the transcription factor Fli-1 in murine lupus development by regulation of interleukin-6 expression. Arthritis Rheumatol 2014;66:3436&#x2013;44. 10.1002/art.38818</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38818</ArticleId><ArticleId IdType="pmc">PMC4245454</ArticleId><ArticleId IdType="pubmed">25155007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennard Richard ML, Sato S, Suzuki E, et al. . The Fli-1 transcription factor regulates the expression of CCL5/RANTES. J Immunol 2014;193:2661&#x2013;8. 10.4049/jimmunol.1302779</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302779</ArticleId><ArticleId IdType="pmc">PMC4157095</ArticleId><ArticleId IdType="pubmed">25098295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennard Richard ML, Brandon D, Lou N, et al. . Acetylation impacts fli-1-driven regulation of granulocyte colony stimulating factor. Eur J Immunol 2016;46:2322&#x2013;32. 10.1002/eji.201646315</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646315</ArticleId><ArticleId IdType="pmc">PMC5175580</ArticleId><ArticleId IdType="pubmed">27431361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou N, Lennard Richard ML, Yu J, et al. . The Fli-1 transcription factor is a critical regulator for controlling the expression of chemokine C-X-C motif ligand 2 (cxcl2). Mol Immunol 2017;81:59&#x2013;66. 10.1016/j.molimm.2016.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.11.007</ArticleId><ArticleId IdType="pubmed">27889620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Zhang XK, Temmoku J, et al. . Ets family transcription factor Fli-1 promotes leukocyte recruitment and production of IL-17A in the MRL/lpr mouse model of lupus nephritis. Cells 2020;9:714. 10.3390/cells9030714</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9030714</ArticleId><ArticleId IdType="pmc">PMC7140643</ArticleId><ArticleId IdType="pubmed">32183259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Lennard Richard M, Li P, et al. . Expression of GM-CSF is regulated by Fli-1 transcription factor, a potential drug target. J Immunol 2021;206:59&#x2013;66. 10.4049/jimmunol.2000664</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000664</ArticleId><ArticleId IdType="pmc">PMC7942804</ArticleId><ArticleId IdType="pubmed">33268481</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang X, Oates JC, Helke KL, et al. . Camptothecin and topotecan, inhibitors of transcription factor fli&#x2010;1 and topoisomerase, markedly ameliorate lupus nephritis in (NZB &#xd7; NZW) F1 mice and reduce the production of inflammatory mediators in human renal cells. Arthritis Rheumatol
2021;73:1478&#x2013;88. 10.1002/art.41685
Available: https://onlinelibrary.wiley.com/toc/23265205/73/8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41685</ArticleId><ArticleId IdType="pmc">PMC9853877</ArticleId><ArticleId IdType="pubmed">33559345</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiou P, Maroulakou I, Green J, et al. . Expression of ets family of genes in systemic lupus erythematosus and sjogren&#x2019;s syndrome. Int J Oncol 1996;9:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">21541474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay M, Oswald M, Sanchez-Guerrero J, et al. . Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. Lupus Sci Med 2016;3:e000159. 10.1136/lupus-2016-000159</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000159</ArticleId><ArticleId IdType="pmc">PMC5133406</ArticleId><ArticleId IdType="pubmed">27933197</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Wu Y, Hamlett ED, et al. . Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer&#x2019;s disease. Mol Ther 2022;30:1451&#x2013;64. 10.1016/j.ymthe.2022.01.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.01.023</ArticleId><ArticleId IdType="pmc">PMC9077320</ArticleId><ArticleId IdType="pubmed">35038582</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorraji SE, Kanapathippillai P, Hovd A-M, et al. . Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am J Pathol 2020;190:2203&#x2013;25. 10.1016/j.ajpath.2020.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.07.015</ArticleId><ArticleId IdType="pubmed">32818496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Boor P, Fukuma S, et al. . Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. Kidney Int 2020;98:448&#x2013;63. 10.1016/j.kint.2020.02.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.02.023</ArticleId><ArticleId IdType="pubmed">32473779</ArticleId></ArticleIdList></Reference><Reference><Citation>Lema GPD, Maier H, Nieto E, et al. . Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001;12:1369&#x2013;82. 10.1681/ASN.V1271369</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V1271369</ArticleId><ArticleId IdType="pubmed">11423566</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah K, Lee W-W, Lee S-H, et al. . Dysregulated balance of th17 and th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R53. 10.1186/ar2964</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2964</ArticleId><ArticleId IdType="pmc">PMC2888202</ArticleId><ArticleId IdType="pubmed">20334681</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Xiao C, Feng Z, et al. . Sox4 promotes the growth and metastasis of breast cancer. Cancer Cell Int 2020;20:468. 10.1186/s12935-020-01568-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-020-01568-2</ArticleId><ArticleId IdType="pmc">PMC7523060</ArticleId><ArticleId IdType="pubmed">33005101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Mallampati S, Gong Y, et al. . Sox4 is required for the survival of pro-B cells. J Immunol 2013;190:2080&#x2013;9. 10.4049/jimmunol.1202736</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202736</ArticleId><ArticleId IdType="pmc">PMC3578124</ArticleId><ArticleId IdType="pubmed">23345330</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwahara M, Yamashita M, Shinoda K, et al. . The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-&#x3b2; and suppresses T (H) 2 differentiation. Nat Immunol 2012;13:778&#x2013;86. 10.1038/ni.2362</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2362</ArticleId><ArticleId IdType="pmc">PMC3477402</ArticleId><ArticleId IdType="pubmed">22751141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao DA. T cells that help B cells in chronically inflamed tissues. Front Immunol 2018;9:1924. 10.3389/fimmu.2018.01924</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01924</ArticleId><ArticleId IdType="pmc">PMC6115497</ArticleId><ArticleId IdType="pubmed">30190721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitomi H, Kobayashi S, Miyagawa-Hayashino A, et al. . Human SOX4 facilitates the development of cxcl13-producing helper T cells in inflammatory environments. Nat Commun 2018;9:3762. 10.1038/s41467-018-06187-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06187-0</ArticleId><ArticleId IdType="pmc">PMC6145936</ArticleId><ArticleId IdType="pubmed">30232328</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi T, Miyagawa T, Toyama S, et al. . Cxcl13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. Exp Dermatol 2018;27:1030&#x2013;7. 10.1111/exd.13724</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.13724</ArticleId><ArticleId IdType="pubmed">29947047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Guo J, Ding R, et al. . Cxcl13 blockade attenuates lupus nephritis of MRL/lpr mice. Acta Histochem 2015;117:732&#x2013;7. 10.1016/j.acthis.2015.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acthis.2015.09.001</ArticleId><ArticleId IdType="pubmed">26456520</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang MW, Stock AD, Putterman C. Cxcl13 neutralization attenuates neuropsychiatric manifestations in lupus-prone mice. Front Immunol 2021;12:763065. 10.3389/fimmu.2021.763065</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.763065</ArticleId><ArticleId IdType="pmc">PMC8633419</ArticleId><ArticleId IdType="pubmed">34868008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>